ArticleJCEM case reports2026
Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in an adolescent with type 2 diabetes.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Youth-onset type 2 diabetes (T2D) is increasing, prompting expanded use of pharmacotherapies previously approved only for adults. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, approved for pediatric use in 2023, improve glycemic control by promoting glucosuria, but they carry a known risk of euglycemic diabetic ketoacidosis (DKA) in adults. We describe a unique pediatric case of SGLT2 inhibitor-associated euglycemic DKA in a 12-year-old female with T2D. The patient developed DKA with normal glucose shortly after initiating an SGLT2 inhibitor, leading to diagnostic uncertainty and recognition only after exclusion of more common etiologies. She was successfully treated with intravenous insulin and fluids with resolution of DKA and subsequently transitioned to subcutaneous insulin therapy. This case underscores that euglycemic DKA can occur in youth receiving SGLT2 inhibitors, particularly during puberty when physiologic insulin resistance may heighten risk, and that subtle presentations can complicate early recognition if clinicians rely on hyperglycemia alone. As SGLT2 inhibitors enter broader pediatric use, heightened diagnostic vigilance, guided assessment of ketones and acid-base status in symptomatic patients, and patient and family education are essential to ensure safe use in children and adolescents with T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.